Mozart Therapeutics is a clinical-stage biopharmaceutical company committed to developing disease-modifying therapies that restore healthy immune system function in patients with autoimmune disease.
Our first-in-class CD8 Treg modulators target a fundamental cause of immune surveillance dysregulation to restore durable immune homeostasis across autoimmune disorders.
Our Science
Building on the seminal work of Professor Mark Davis, who identified a novel immune network and characterized the breadth and functionality of regulatory CD8 T cells (CD8 Treg), we are developing first-in-class biologics to modulate CD8 Treg dysfunction.
Pipeline
Mozart is advancing a pipeline of novel CD8 Treg modulators designed to restore durable immune homeostasis and avert the progressive inflammation and tissue damage caused by pathogenic autoimmune responses.